|ID||Components||Size(96 tests)||Size (480 tests)|
|TAS003-C01||SARS-CoV-2 S protein RBD||10ug||60ug|
|TAS003-C02||Biotinylated Human ACE2||10ug||10ug|
|SAD-S35||Anti-SARS-CoV-2 neutralizing antibody||20ug||50ug|
Upon receipt, please store the lyophilized products at-20℃. please store the plate and buffer products at 4-8℃ After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
a) Coat the plate with SARS-CoV-2 Spike protein RBD.
b) Add 50ul biotinylated human ACE2 to coated plate.
c) Add the reference in kit or your samples from serum or plasma of interest.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the titer of your samples to inhibit Spike protein RBD: ACE2 binding will be determined by comparing OD readings among different experimental groups.
Determination of Anti-SARS-CoV-2 Neutralizing Antibody titer in different concentrations of human serum.
Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) mesured by SARS-CoV-2 inhibitor screening kit (Cat. No. EP-105) in different concentrations of human serum (CV < 30%).
Price(USD) : $480.00
Price(USD) : $2150.00
Price(USD) : $100.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.